CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk

Constance Baer(Munich Leukemia Laboratory (Germany)), Charles G. Mullighan(St. Jude Children's Research Hospital), Shaina N. Porter(St. Jude Children's Research Hospital), Martha-Lena Mueller(Munich Leukemia Laboratory (Germany)), Paul G. Thomas(St. Jude Children's Research Hospital), Peter Chockley(St. Jude Children's Research Hospital), Aakrosh Ratan(University of Virginia), Shondra M. Pruett‐Miller(St. Jude Children's Research Hospital), Thomas L. Olson(University of Virginia Cancer Center), Tim Flerlage(St. Jude Children's Research Hospital), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), Chunxu Qu(St. Jude Children's Research Hospital), Andrew B. Kleist(Medical College of Wisconsin), James M. Foran(Memorial Sloan Kettering Cancer Center), Manja Meggendorfer(Université Paris-Sud), Torsten Haferlach(Martin Luther Christian University), Wolfgang Kern(Munich Leukemia Laboratory (Germany)), Thomas P. Loughran(University of Virginia Cancer Center), Shunsuke Kimura(St. Jude Children's Research Hospital), Wencke Walter(Munich Leukemia Laboratory (Germany)), Ilaria Iacobucci(St. Jude Children's Research Hospital), Kristine C. Olson(Pennsylvania State University), HeeJin Cheon(California University of Pennsylvania), David J. Feith(University of Virginia), Elisabeth Paietta(Montefiore Medical Center), Laura J. Janke(St. Jude Children's Research Hospital), Mitra S. Rana(St. Jude Children's Research Hospital), M. Madan Babu(St. Jude Children's Research Hospital), Ravi Kalathur(St. Jude Children's Research Hospital)
Nature Genetics
May 1, 2022
Cited by 42


Related Papers